Abstract: A flow device for an exhaust system includes a body that defines an interior cavity. An exhaust inlet passage is disposed in the interior cavity. An exhaust outlet passage is disposed in the interior cavity so that at least a portion of the exhaust inlet passage circumferentially surrounds at least a portion of the exhaust outlet passage. A doser is adapted to inject reductants into the interior cavity of the body such that the reductants are injected in the same general direction as the direction of flow of the exhaust gases.

Abstract: A method for the reduction of corrosion in a treatment unit acid used for separating hydrogen sulfide from and acid gas stream using an alkaline absorption solution. Ions comprising the S2? and/or HS? ions formed by the absorption of the hydrogen sulfide in the absorbent solution are subjected to in situ electrochemical oxidization to form polysulfide ions which form a protective coating on the surfaces of the unit.

Abstract: The present invention relates to an energy efficient carbon dioxide sequestration processes whereby Group 2 silicate minerals and C02 are converted into limestone and sand using a two-salt thermolytic process that allows for the cycling of heat and chemicals from one step to another.

Abstract: A dual function catalytic filter is provided having a soot filter with an inlet and an outlet, a soot oxidation layer on the inlet, wherein the soot oxidation layer comprises a soot oxidation catalytic component consisting essentially of at least one transition metal dispersed on a cerium and zirconium mixed and/or composite oxide, wherein the at least one transition metal is selected from the group consisting of W, Cr, Ce, Mn, Fe, Co, Ni, Cu, and combinations thereof, and an SCR layer coated on the outlet, wherein the SCR layer comprises an SCR catalytic component. Also provided are methods for removing NOx and soot from a lean burn exhaust gas using the dual function catalytic filter.

Abstract: A storage material for obtaining H-silanes which is present in the form of a hydrogenated polysilane (HPS), as a pure compound or as a mixture of compounds having on average at least six direct Si—Si bonds, the substituenis of which predominantly consist of hydrogen and in the composition of which the atomic ratio of sabstitueot to silicon is at least 1:1.

Abstract: A process for ammonia saturation of a solid material capable of absorbing and desorbing ammonia, the solid material being composed of solid particles and includes placing the solid material in contact with a cooled surface, with the solid material being disposed against the cooled surface in a thin layer having a thickness of less than 100 mm. The process further includes injecting a stream of gaseous ammonia to be in contact with the solid material, while the solid material is in contact with the cooled surface.

Abstract: High-purity iron powder products produced by a low-temperature process by feeding hematite and a reducing agent into a rotary reactor under pressure to form a mechanical fluid bed. The fluid bed is rotated at a particular speed within a rotary reactor. The fluid bed is simultaneously heated to a reaction temperature, and the pressure is then reduced within the rotary reactor to a pressure in a range of 0.01 bars to 2.0 bars, as a result reducing the reaction temperature to a temperature in a range of 600° C. to 850° C. Maintaining the pressure and the rotation results in the formation of a high-purity iron oxide without the requirement for post-grinding process steps because sintering is prevented by using a combination of pressure reduction and a rotary set at an optimum rotation speed, resulting in useful additives produced by a more environmentally-friendly process.

Abstract: Methods, systems, and/or devices for synthesis gas recapture are provided, which may include methods, systems, and/or devices for filtering a synthesis gas stream. In some cases, tars, particulates, water, and/or heat may be removed from the synthesis gas stream through the filtering of the synthesis gas stream. The filtered synthesis gas stream may then be captured and/or utilized in a variety of different ways. Some embodiments utilizing a C—O—H compound to filter a synthesis gas stream. In some embodiments, the C—O—H compound utilized to filter the synthesis gas stream may be utilized to produce additional synthesis gas. The additional synthesis gas may be filtered by additional C—O—H compound.

Abstract: Disclosed is an apparatus and method for capturing the hot humid gases from a gypsum board dryer and utilizing those gases in the production of a synthetic gas (referred to as “syngas”). The syngas produced can then be utilized within a gypsum board plant to reduce the amount of natural gas needed. The method utilizes the heated water vapor (H2O) and carbon dioxide (CO2) found within the flue gas of a board dryer. The H2O and CO2 are used in a gasification process to yield the syngas.

Abstract: Method for preparing molecular sieves and molecular sieves obtained thereby are described. The method includes preparing a reaction mixture, comprising a structure directing agent, at least one source of at least one oxide of a tetravalent element, optionally, one or more sources of one or more oxides selected from the group consisting of oxides of trivalent elements, pentavalent elements, and mixtures thereof, optionally, at least one source of an element selected from Groups 1 and 2 of the Periodic Table; and optionally, hydroxide ions or fluoride ions, and maintaining the reaction mixture under conditions sufficient to form crystals of the molecular sieve. In the method, various imidazolium cations are used as the structure directing element.

Abstract: Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.

Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.

Abstract: Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition.

Abstract: The disclosure provides, in part, fluorocarbon imaging reagents and methods for image-guided treatment and/or diagnosis of a subject with a condition associated with an inflammatory response in an internal organ. The disclosure additionally provides methods for image-guided treatment of myocardial infarction (MI) in a subject.

Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: Described is a new method of treating chronic compartment syndrome in a muscle of a mammal, particularly exertional compartment syndrome. The method includes introducing an effective amount of a nerve-blocking toxin, such as human botulinum toxin into the muscle. Further in addition to treating chronic or exertional compartment syndrome, a method is included and described in the disclosure of confirming diagnosis of exertional compartment syndrome in a muscle of a mammal. In the method, venous compression and/or expansion in a mammal in an area of a muscle having a symptom associated with exertional compartment syndrome is evaluated by comparing venous flow at rest and after stress on the muscle. An anaesthetic is used to block a nerve supplying motor function to the muscle causing compression of a blood vessel. The mammal is evaluated after the block of the nerve to determine if the symptom associated with exertional compartment syndrome is alleviated.

Abstract: The present invention relates to a method of developing a Tumor Model System. The invention deals with a tumor model system with adhesion deprived cells. This observation provides a new method for primary detection of transformation of adhesion-deprived cells and tumorigenicity. The adhesion-deprived cells are capable of metastasizing at distant sites and the model system includes both the tumor formation and metastasis.

Abstract: Methods, compositions and kits are provided for enhancing remineralization of a tooth or bone containing hydroxyapatite and inhibiting caries progression or loss of hydroxyapatite using a bisphosphonate or pyrophosphonate. The tooth or tooth surface contains a trauma or defect, for example the tooth contains a caries that is identified using a detectable probe. The bisphosphonate or pyrophosphonate is contacted to the tooth and/or oral cavity and binds to the hydroxyapatite material in the tooth or bone and prevents loss of hydroxyapatite material or strengthens the hydroxyapatite. The amount and extent of enhanced remineralization or of inhibition of caries progression and loss of hydroxyapatite are determined by techniques including photography, light microscopy and fluorescence microscopy.

Abstract: The present invention relates to non-invasive methods of in vivo selecting an antibody against a desired target on the surface of a mammalian cell of a subject by applying near-infrared fluorescence imaging (NIRF) as well as uses of NIRF in such methods. In addition, kits for the use in these methods comprising a panel of potentially therapeutic effective fluorescence labeled antibodies and means for NIRF imaging are provided.

Abstract: Methods to to enhance solubility of butyl methoxydibenzoylmethane and/or bis-ethylhexyloxyphenol methoxyphenyl triazine in a cosmetic oil suitable as a solvent for butyl methoxydibenzoylmethane and/or bis-ethylhexyloxyphenol methoxyphenyl triazine are provided which include incorporating a solubility enhancing effective amount of a polyglycerol based UV filter in such cosmetic oil.

Abstract: A nail enamel composition has a film-forming mixture and an accelerator mixture. The film-forming mixture includes 9-28% nitrocellulose, by weight, in a suitable solvent. The accelerator mixture includes acetone and/or ethyl acetate. The composition further includes less than 1% cyanoacrylate, by weight. The nail enamel composition is substantially free of graphite fibers.

Abstract: The present invention relates to a solid cosmetic composition in the form of a compact powder, comprising, in a physiologically acceptable medium, at least: —a pulverulent phase in an amount of greater than or equal to 35% by weight relative to the total weight of the composition, —a liquid fatty phase comprising at least one non-volatile oil, and—at least one amorphous hydrocarbon-based block copolymer. The present invention also relates to a process for coating the face, and in particular the eyelids, with the said cosmetic composition.

Abstract: The present invention provides a lip cosmetic that has excellent secondary adhesion resistance effect immediately after the application and is excellent in gloss and stability. The lip cosmetic of the present invention is characterized by comprising the following (a) and (b), wherein the blending quantity of (b) is 20 to 70 mass %: (a) 5 to 20 mass % of a polyglyceryl isostearate wherein the addition mole number of glycerin is 4 to 10, and the number of isostearic acid residues is 1 to 4; and (b) (b1) 20 to 70 mass % of a methyl phenyl silicone, (b2) 0 to 45 mass % of a pentaerythritol ester.

Abstract: Disclosed is a method of reducing or avoiding staining in or on clothing caused by a cosmetic or dermatological preparation comprising one or more antiperspirant substances and/or of improving the ability of stains in or on clothing which are caused at least in part by said preparation to be washed out from the clothing. The method comprises including in the preparation one or more cationic surfactants.

Abstract: Disclosed is cosmetic or dermatological preparation which is present as an aerosol spray and comprises one or more antiperspirant substances and one or more cationic surfactants.

Abstract: Compositions for use with a mascara applicator with vibrating applicator head. The frequency, amplitude and geometry of the vibrating head are sufficient to significantly alter the rheological properties of thixotropic and anti-thixotropic mascara compositions, including an effect that persists after the vibration has stopped. The mascara may be manipulated for improved results, greater flexibility in formulation, benefits in manufacture, as well as other benefits.

Abstract: Hair care compositions including from about 0.005% to about 5% apigenin; from about 0.15% to about 12% of a solubilizing agent, wherein the solubilizing agent comprises an amine functional group; and at least about 20 weight percent of an aqueous carrier, where the composition has a pH ranging from about 3 to about 10, and methods of making the same are provided. These hair care compositions can be applied to any area of the scalp or hair where healthier hair appearance is desired.

Abstract: Agents for the temporary shaping of keratinic fibers include in a cosmetically acceptable carrier—relative in each case to the weight thereof—1 to 20 wt. % of at least one crosslinked, amphiphilic, anionic polymer comprising at least one structural unit of formula (I) as described herein and at least one structural unit of formula (II) as described herein, and 1 to 20 wt. % of at least one uncrosslinked, anionic polymer comprising at least one structural unit of formula (III) as described herein and at least one structural unit of formula (IV) as described herein, and 1 to 40 wt. % of at least one fixing non-ionic polymer from the group comprising (c1) non-ionic polymers having at least one structural element of formula (N5) as described herein, (c2) homopolymers and non-ionic copolymers of N-vinylpyrrolidone, and (c3) non-ionic copolymers of isobutene.

Abstract: Agents for the temporary shaping of keratinic fibers are characterized by a pleasant product feel, light consistency and a lightweight application. The agents include in a cosmetically acceptable carrier, relative in each case to the total agent, 0.1 to 15 wt. % of monoesters of optionally alkylated sugars with C6-C30 fatty acids, 0.1 to 15 wt. % of diesters of optionally alkylated sugars with C6-C30 fatty acids, 0 to 50 wt. % of at least one film-forming polymer, 0 to 50 wt. % of at least one wax with a melting point in a range from 40° C. to 90° C., with the proviso that the proportion of component(s) c) and d) in the cosmetic agent is 0.2 to 50 wt. %.

Abstract: Agents for treating keratin-containing fibers, in particular human hair, containing, in a cosmetically acceptable carrier: at least one anionic setting copolymer encompassing at least one structural unit of formula (I) and at least one structural unit of formula (II) and at least one structural unit of formula (III), in which R1 denotes a hydrogen atom or a methyl group, R2 denotes a hydrogen atom or a methyl group, R3 denotes a branched (C1 to C20) alkyl group, a branched (C2 to C6) hydroxyalkyl group, or a *-(CH2CH2O)n—R6 group where R6=branched (C1 to C20) alkyl and n=1 to 30, R4 and R5 denote a hydrogen atom, or one of the two residues denotes a hydrogen atom and the other a methyl group, are suitable for temporary reshaping of hair and for imparting shine, in particular as an aerosol hair spray or aerosol hair foam.

Abstract: Disclosed is a composition for preventing hair loss or promoting hair restoration and for enhancing hair health, the composition comprising an active ingredient in the form of soy extract extracted using a C1 to C5 alcohol at a concentration of between 1% and 70% (v/v).

Abstract: The present invention relates to a stable, aqueous freshener composition for the reduction or elimination of malodors in air and on fabrics. The composition comprises from about 0.1% to about 3.0% by weight, hydrogen peroxide as a malodor oxidant; an effective level of undecylenic acid (and/or derivative thereof) as a malodor absorber preblended with a fragrance; a surfactant to solubilize the fragrance/malodor absorber blend; an acid based stabilizer in a range from about 0.008% to about 0.60% by weight; an optional pH buffer; and an aqueous carrier. The composition can be delivered via a spray dispenser for treatment of indoor air and fabrics. The composition has a pH of less than about 6 and does not contain ingredients known to soil, stain or damage fabrics. When applied as a fine mist, the composition delivers effective control of a broad range of malodors, while remaining imperceptible on surfaces when dry.

Abstract: The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight L-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye.

Abstract: The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid.

Abstract: Disclosed are dsRNA constructs and methods to control insects via double stranded RNA interference of insect PBAN receptor genes.

Abstract: Systems and methods for inhibiting bone loss using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) either in vivo or ex vivo. The FoxP3+ CD8 T-cells (TcREG) are provided to the patient to subsequently regulate osteoclast function, thereby establishing a bi-directional regulatory loop between osteoclasts and FoxP3+ CD8 T-cells(TcREG).

Abstract: Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions.

Abstract: The disclosure relates to methods and compositions for preventing or inhibiting pathogenic bacterial infections in a subject caused by pathogenic bacteria expressing a multivalent adhesion molecule (MAM) polypeptide by administering to a subject a composition comprising a MAM polypeptide or a non-pathogenic bacterium expressing a MAM polypeptide, or a combination thereof.

Abstract: The present invention relates to the gut microbiome as a biomarker and therapeutic target for energy harvesting, weight loss or gain, and/or obesity in a subject. In particular, the invention provides methods of altering and monitoring the relative abundance of Bacteroides and Firmicutes in the gut microbiome of a subject.

Abstract: Selection of probiotic strains belonging to the genus Bifidobacterium and to a symbiotic composition containing the same for use of feeding infants, is described.

Abstract: The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.

Abstract: One aspect provides a method of forming a mineralized material by co-culturing a epithelial cell, such as ameloblasts, and mesenchymal cells, such as osteoblasts or odontoblasts, in a mineral-stimulating medium. Another aspect provides matrix seeded with epithelial cells and mesenchymal cells and infused with a mineral-stimulating medium capable of forming a mineralized material in the matrix. Methods of manufacturing such compositions and methods of treating mineralization-related conditions are also provided.

Abstract: The present invention relates to a method of preparing a population of stem cells for autologous implantation to a subject. The cells are activated by irradiating the cells with one or more wavelengths of yellow and red and/or green light. In particular, the cells are irradiated with 575-595 nm (5-20 mW), and 630-635 nm or 660-670 nm (10-100 mW) and/or 510-540 nm (10-60 mW) of monochromatic light for 30-60 mins. Preferably the stem cells are adipose-derived stem cells. Also the invention relates to therapeutic applications of the activated stem cells.

Abstract: A pharmaceutical or nutraceutical composition comprising a cell line callus culture of grape berry cells grown in vitro, whereby the cell line callus culture of grape berry cells is derived from one or more of grape-berry cross section, grape-berry skin, grape-berry flesh, grape seed, grape embryo of seeded or seedless cultivars or grape seed coat.

Abstract: A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.

Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.

Abstract: The present invention relates to a novel method for preparing induced pluripotent stem cells (iPSCs) by introducing three genes, Oct3/4, Sox2, and Parp1, into somatic cells. The present invention also relates to the iPSCs produced by the aforementioned method. Also provided is a method of rejuvenating cells by use of a PARylated protein or an enzyme with PARylation activity. Further provided is a method for inducing the secretion of interferon-? inducible protein-10 (IP-10) comprising administering to a subject in need thereof an effective amount of iPSCs or iPSC-CM.

Abstract: The present invention is related to the field of bioprotection, in particular to an antimicrobial composition comprising a Lactobacillus rhamnosus strain and/or a Lactobacillus paracasei strain. Furthermore, the present invention concerns uses for such an antimicrobial composition, food, feed and pharmaceutical products comprising such an antimicrobial composition, a method of manufacturing such food, feed and pharmaceutical products and a method for reducing the content of unwanted microorganisms of such food, feed and pharmaceutical products.

Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.